Ann: Race Oncology Share Purchase Plan Opens, page-400

From pp.5-6 of "Share Purchase Plan Offer Booklet" available from Automic:

[Start quote]

Use of Funds

The manner in which the funds will be used is dependent on the amount raised. Set out below are 3 different examples using base, mid and full case examples:

Base Case – If a total of $12 million is raised: Phase 1/2 FTO solid tumour clinical trial ($8.0 million); Improved formulations of Zantrene® ($2.2 million); Preclinical cardioprotection studies ($1.0 million); and the development of new molecules ($0.8 million).

Mid Case – If a total of $19.9 million is raised: Phase 1/2 FTO solid tumour clinical trial ($8.0 million); Cardio-protection Phase 2b clinical trial in breast cancer patients ($7.5 million) ; Improved formulations of Zantrene® ($2.6 million); Preclinical cardio-protection studies ($1.0 million); and the development of new molecules ($0.8 million).

Full Case – If a total of $27.9 million is raised: Phase 2 EMD AML/MDS clinical trial in Europe ($9.2 million); Phase 1/2 FTO solid tumour clinical trial ($8.0 million); Cardioprotection Phase 2b clinical trial in breast cancer patients ($7.5 million); Improved formulations of Zantrene® ($3.2 million); Preclinical cardio-protection studies ($1.0 million); and the development of new molecules ($0.8 million).

[End quote]